Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to
stop the growth of abnormal blood cells, either by killing the cells or by stopping them from
dividing. Giving cyclophosphamide together with donor lymphocytes that have been treated in
the laboratory may be an effective treatment for myelodysplastic syndromes or
myeloproliferative disorders.
PURPOSE: This clinical trial is studying the best dose of donor lymphocytes when given
together with cyclophosphamide in treating patients with myelodysplastic syndromes or
myeloproliferative disorders.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins